INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Bausch + Lomb Corporation and its executives [1] Group 1: Product Recall and Stock Impact - On March 27, 2025, Bausch + Lomb announced a voluntary recall of intraocular lenses due to reports of toxic anterior segment syndrome, leading to a stock price drop of $1.54 per share, or 9.83%, closing at $14.13 on March 28, 2025 [3] - Following the recall, on April 30, 2025, Bausch + Lomb reported an adjusted net loss of $54 million for Q1 2025, a significant decline from an adjusted net income of $24 million in Q1 2024 [4] - The company revised its full-year growth outlook down to 4.5% to 6.5%, from a previous estimate of 5.5% to 7.5%, citing the impact of the enVista product recall [4] - On the same day, the stock price fell by $2.16 per share, or 15.74%, closing at $11.56 [5] Group 2: Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is leading the investigation into Bausch + Lomb's practices, emphasizing its long history of fighting for victims of securities fraud [6]